Fresenius Medical Care accelerates share buyback with €415 million tranche

Fresenius Medical Care (NYSE: FMS, Frankfurt: FME) announced it will accelerate the second tranche of its €1 billion share buyback program, planning to repurchase approximately €415 million worth of shares from January 12 to May 8, 2026.

The dialysis provider completed the first tranche of its buyback program on December 29, 2025, ahead of schedule. The company now expects to complete the entire €1 billion program in less than a year, significantly earlier than originally planned when announced during its Capital Markets Day on June 17, 2025.

"The successful acceleration of our €1 billion share buyback program is supported by our strong financial performance and consistent execution against our 'FME Reignite' strategy, with a focus on value creation and delivering returns to our shareholders," said Helen Giza, CEO and Chair of the Management Board.

CFO Martin Fischer attributed the acceleration to strong cash-flow generation and continued business momentum, stating it demonstrates the effectiveness of the company's capital allocation framework.

The share buyback program forms part of Fresenius Medical Care's capital allocation framework within its 'FME Reignite' strategy. The company operates 3,628 dialysis clinics globally and provides dialysis treatments for approximately 294,000 patients worldwide.

Fresenius Medical Care will provide regular updates on the buyback program's progress through its investor relations website.

You May Also Be Interested In

• Teleflex sells OEM business for $1.5B, plans debt cuts
• American Strategic Investment Co. to release Q2 2026 results Aug. 12
• Fresenius Medical Care appoints Cassie McLean as new Management Board Member for Care Delivery